Author
Listed:
- Susan O’Connell
(Cardiff and Vale University Health Board)
- Megan Dale
(Cardiff and Vale University Health Board)
- Helen Morgan
(Cardiff University)
- Kimberley Carter
(National Institute for Health and Care Excellence)
- Rhys Morris
(Cardiff and Vale University Health Board)
- Grace Carolan-Rees
(Cardiff and Vale University Health Board)
Abstract
Cluster headaches are excruciating attacks of pain that can last between 15 min and 3 h. Cluster headaches can be episodic, where patients have long pain-free intervals between attacks, or chronic, where they do not. As part of the Medical Technologies Evaluation Programme, the UK National Institute for Health and Care Excellence (NICE) considered the clinical effectiveness and cost impact of gammaCore (electroCore), a handheld, patient-controlled device used to treat and prevent cluster headache. gammaCore is a non-invasive vagus nerve stimulator, the aim of which is to modify pain signals by stimulating the vagus nerve through the skin of the neck. Evidence suggests that gammaCore reduces the intensity and frequency of cluster headaches and that the addition of gammaCore to standard care is cost saving. Therefore, the guidance published by NICE in December 2019 recommends routine adoption of gammaCore into the UK national health service. However, the guidance noted that gammaCore does not work for everyone and recommended that treatment with gammaCore should stop after 3 months in patients whose symptoms do not improve.
Suggested Citation
Susan O’Connell & Megan Dale & Helen Morgan & Kimberley Carter & Rhys Morris & Grace Carolan-Rees, 2021.
"gammaCore for Cluster Headaches: A NICE Medical Technologies Guidance,"
PharmacoEconomics - Open, Springer, vol. 5(4), pages 577-586, December.
Handle:
RePEc:spr:pharmo:v:5:y:2021:i:4:d:10.1007_s41669-021-00276-5
DOI: 10.1007/s41669-021-00276-5
Download full text from publisher
Corrections
All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:spr:pharmo:v:5:y:2021:i:4:d:10.1007_s41669-021-00276-5. See general information about how to correct material in RePEc.
If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.
We have no bibliographic references for this item. You can help adding them by using this form .
If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.
For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.springer.com .
Please note that corrections may take a couple of weeks to filter through
the various RePEc services.